Published in final edited form as:

J Clin Psychiatry. 2015 April ; 76(4): 440–446. doi:10.4088/JCP.14m09044.

Six-Month Outcomes from a Randomized Trial Augmenting Serotonin Reuptake Inhibitors with Exposure and Ritual Prevention or Risperidone in Adults with Obsessive-Compulsive Disorder

Edna B. Foa, Ph.D.^{1,*}, Helen Blair Simpson, M.D., Ph.D.^{2,3,*}, David Rosenfield, Ph.D.⁴, Michael R. Liebowitz, M.D.³, Shawn P. Cahill, Ph.D.⁵, Jonathan D. Huppert, Ph.D.^{1,6}, James Bender Jr, Psy.D.², Carmen P. McLean, Ph.D.¹, Michael J. Maher, Ph.D.², Raphael Campeas, M.D.^{2,3}, Chang-Gyu Hahn, M.D., Ph.D.¹, Patricia Imms, R.N.¹, Anthony Pinto, Ph.D.^{2,3}, Mark B. Powers, Ph.D.⁷, Carolyn I. Rodriguez, M.D., Ph.D.^{2,3}, Page E. Van Meter, Ph.D.², Donna Vermes, P.M.H.N.P.², and Monnica T. Williams, Ph.D.⁸

¹Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA

²Division of Clinical Therapeutics, New York State Psychiatric Institute, New York, NY

³Department of Psychiatry, Columbia University, New York, NY

⁴Department of Psychology, Southern Methodist University, Dallas, TX

⁵Department of Psychology, University of Wisconsin – Milwaukee, Milwaukee, WI

⁶Department of Psychology, The Hebrew University of Jerusalem, Jerusalem, Israel

⁷Department of Psychology, University of Texas at Austin, Austin, TX

⁸Department of Psychological & Brain Sciences, University of Louisville, Louisville, KY

Abstract

Objective—To compare outcomes after six-month maintenance treatment of adults diagnosed with OCD based on DSM IV criteria who responded to acute treatment with serotonin reuptake inhibitors (SRIs) augmented by exposure therapy (EX/RP) or risperidone.

Method—A randomized trial was conducted at two academic sites from October 2006 through December 2012. In the Acute Phase, 100 patients on therapeutic SRI dose with at least moderate OCD severity were randomized to 8 weeks of EX/RP, risperidone, or pill placebo. Responders

Corresponding Author: Dr. Edna B. Foa, University of Pennsylvania, School of Medicine, Department of Psychiatry, 3535 Market Street, 6th Floor, Philadelphia, PA 19104, Tel. 215-746-3327, Fax. 215-746-3311, foa@mail.med.upenn.edu.

*The first two authors contributed equally.

Author Contributions: Drs. Foa and Simpson had full access to all of the data in the study and take responsibility for the integrity of the data and, with Dr. Rosenfield (the statistician), the accuracy of the data analysis. Drs. Foa and Simpson made equal contributions. Conception and design: Foa, Simpson, Liebowitz, Huppert, and Campeas. Acquisition of data: Simpson, Huppert, Cahill, Maher, McLean, Bender, Williams, Vermes, Van Meter, Rodriguez, Powers, Pinto, Imms, Hahn, and Campeas. Analysis and interpretation of data: Foa, Simpson, Liebowitz, Huppert, Cahill, Rosenfield, Weaver, Van Meter. Drafting of the manuscript: Foa, Simpson, Rosenfield, and McLean. All authors were involved in the critical revision of the manuscript for important intellectual content. All authors approved of the final version of the manuscript to be published.

Conflict of Interest/Financial Disclosures: The remaining authors report no competing interests.

entered the six-month Maintenance Phase, continuing the augmentation strategy they received acutely (30 EX/RP, 8 risperidone). Independent evaluations were conducted every month. The main outcome was the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).

Results—Intent-to-treat analyses indicated that EX/RP yielded superior OCD outcomes after six-month maintenance treatment than risperidone (Y-BOCS=10.95 versus 18.70; $t(40)=2.76, P=.009$); more patients randomized to EX/RP met response criteria (Y-BOCS decrease $\geq 25\%$: 70% versus 22.5%; $P<.001$) and achieved minimal symptoms (Y-BOCS ≤ 12 : 50% versus 5%; $P<.001$). During maintenance, OCD severity decreased slightly in both conditions (Y-BOCS decrease=2.2 points, $P=.020$). Lower Y-BOCS at entry to maintenance was associated with more improvement in both conditions ($r(38)=-.57, P<.001$).

Conclusion—OCD patients on SRIs who responded to acute EX/RP or risperidone maintained their gains over six-month maintenance. Because EX/RP patients improved more during acute treatment than risperidone patients, and both maintained their gains during maintenance, EX/RP yielded superior outcomes six months later. The findings that 50% of patients randomized to EX/RP had minimal symptoms at six-month maintenance, a rate double that of prior studies, suggests that EX/RP maintenance helps maximize long-term outcome.

Trial Registration—[Clinicaltrials.gov](https://clinicaltrials.gov/ct2/show/study/NCT00389493) identifier: [NCT00389493](https://clinicaltrials.gov/ct2/show/study/NCT00389493)

Introduction

Serotonin reuptake inhibitors (SRIs, i.e., clomipramine and selective SRIs) are the only medications approved by the Food and Drug Administration to treat obsessive-compulsive disorder OCD¹. Although many patients respond, few achieve minimal symptoms from an SRI alone². For partial SRI responders, practice guidelines¹ recommend adding either cognitive-behavioral therapy (CBT) consisting of Exposure and Response Prevention (EX/RP) or antipsychotics. This paper compared the outcome of these two SRI augmentation strategies when continued for six months after acute treatment.

Randomized controlled trials and naturalistic studies find that adding EX/RP to SRIs improves outcomes in adults with OCD, irrespective of whether they responded to the SRI^{3–7}. In one prior study of adults with OCD on SRIs who received 8 weeks of EX/RP augmentation⁸, 40 of 54 (74%) responded to acute treatment, and 22 of 54 (41%) met response criteria after six months of maintenance.

Meta-analyses^{9, 10} estimate that up to one-third of OCD patients on SRIs respond acutely to antipsychotic augmentation. However, the long-term response to antipsychotic augmentation has not been systematically studied. Matsunaga and colleagues¹¹ assigned OCD patients on SRIs (based on their degree of response) to continued SRI plus EX/RP ($n=46$, for SRI responders) or continued SRI plus EX/RP plus an antipsychotic ($n=44$, for SRI non-responders). At the time of assignment and one year later, the SRI nonresponders (receiving continued SRI, EX/RP, and antipsychotic) had significantly more OCD symptoms than the SRI responders (receiving continued SRI and EX/RP). Also, mean improvement in OCD symptoms over the year was smaller for the SRI nonresponders. These findings led the authors to question the long-term effectiveness of antipsychotic augmentation. However, because treatment assignment was not random but based on SRI response and both groups

received EX/RP, the study could not ascertain the long-term effects of augmenting SRIs with antipsychotics alone.

To compare the long term effects of EX/RP versus risperidone augmentation, we analyzed data from a trial that randomized 100 OCD adults on SRIs to EX/RP, risperidone, or pill placebo. After 8 weeks of acute treatment, EX/RP was superior to both risperidone and pill placebo¹². Responders then continued to receive their assigned treatment for an additional six months. We hypothesized that after the six-month Maintenance Phase, patients randomized to EX/RP would have superior OCD outcome to those randomized to risperidone.

Method

Setting

Data came from a randomized controlled trial conducted at two academic outpatient clinics in Philadelphia and New York City. Study details appear elsewhere¹². Enrollment began in 2007; data collection ended in 2012. Each site's institutional review board approved the study. Participants provided written informed consent prior to entry.

Participants

Eligible participants were adults (18–70 years) with a principal diagnosis of OCD (one year), who were receiving an SRI at a stable dose for at least 12 weeks and yet remained symptomatic (Yale Brown Obsessive-Compulsive Scale Y-BOCS^{13, 14} 16). Exclusion criteria included bipolar and psychotic disorders, substance abuse or dependence in the past 3 months, prominent suicidal ideation, a 17-item Hamilton Depression Rating Scale HDRS¹⁵ score indicating severe depression (> 25), or hoarding as the only OCD symptom. Other Axis I diagnoses were permitted if OCD was the most severe and impairing. Patients were excluded if they had previously received risperidone (0.5 mg/day for 8 weeks) or EX/RP (8 sessions over 2 months) while taking an SRI (as described above) or were receiving their first SRI with no response, as practice guidelines¹ recommend switching to another SRI in such cases. Trained clinicians determined eligibility. Trained raters with expertise in OCD and related disorder confirmed psychiatric diagnoses prior to study entry using the Structured Clinical Interview for DSM-IV¹⁶. Treatment history was confirmed with the referring clinician and/or chart review.

Study Procedures

During the Acute Phase, 100 adults with OCD on a stable SRI dose were randomized to augmentation by EX/RP ($n=40$), risperidone ($n=40$), or pill placebo ($n=20$) (Figure 1). Patients randomized to EX/RP saw a study therapist for two planning/introductory sessions and 15 twice-weekly 90-minute EX/RP sessions¹⁷, and met with a study psychiatrist for SRI maintenance at Weeks 0, 4, and 8. Those randomized to risperidone or pill placebo met with a study psychiatrist at Weeks 0, 1, 2, 3, 4, 6, and 8.

Responders at Week 8 (Y-BOCS decrease 25%) were eligible to enter the six-month Maintenance Phase; non-responders were referred for open treatment. During maintenance,

responders continued their SRI at the same dose (meeting monthly with their study psychiatrist) and the augmentation strategy to which they were originally assigned (EX/RP with their study therapist or risperidone). For EX/RP patients, maintenance sessions included exposures, ritual prevention (following standard procedures¹⁷) and instruction in relapse prevention. The length and frequency of maintenance EX/RP sessions depended upon the patient's OCD severity. Patients who achieved minimal symptoms at the end of the Acute Phase (Y-BOCS = 12) received four weekly 45-minute sessions followed by 45-minute sessions every other week for the duration of the Maintenance Phase. The remaining patients received 90-minute EX/RP sessions twice-weekly until they achieved minimal symptoms (Y-BOCS = 12) or had received 15 additional 90-minute EX/RP sessions. Subsequently, patients received four weekly 45-minute sessions followed by 45-minute sessions every other week until the end of the Maintenance Phase. Risperidone patients received ongoing risperidone, with the intent of maintaining the same dose used during the Acute Phase. Consistent with clinical practice, however, medication decreases for side effects and increases for OCD symptom exacerbations were allowed, so long as the dose stayed between 0.5 and 4.0 mg/day, reflecting doses used in prior risperidone augmentation studies in OCD^{18–20}.

Assessments

Sociodemographic features and treatment history were assessed at baseline. Independent evaluators (IEs), blind to treatment, evaluated patients every four weeks during the Acute (weeks 0,4,8) and Maintenance Phases (weeks 12,16,20,24,28,32). The IE training included reviewing tapes of senior IEs conducting evaluations, re-rating these tapes with a goal of achieving at least 90% agreement with the original ratings, and observing at least 2 live evaluations by senior IEs. In addition, IEs conducted at least 2 evaluations with the senior IE in the room, with the goal of achieving at least 90% agreement with the senior IE. During the study, IEs audiotaped their assessments and these were sent to the IE supervisor (Dr. Jonathan Huppert) for review. IEs at each site conducted ongoing reliability meetings for the Y-BOCS in which all the IEs rated the audiotaped assessments. Ratings were compared afterward and any divergences were resolved. In addition, IEs from both sites met with Dr. Huppert in person or by conference call twice per year, and taped interviews from each site were formally rated by all IEs to assess inter-rater and cross-site reliability, and any points of divergence were resolved. Intraclass correlations (ICC) between IEs were extremely high (e.g., Y-BOCS ICC=0.99; 95% CI=0.97, 1.00).

IEs administered the Y-BOCS^{13, 14} to assess OCD severity, the 17-item HRDS¹⁵ to assess depressive severity, and the Brown Assessment of Beliefs (BABS²¹) to assess degree of insight about the main OCD belief. Every four weeks, patients also completed the Quality of Life Satisfaction Scale-Short Form (QLESQ²²), the Social Adjustment Scale-Self Report (SAS²³), and the Obsessive-Compulsive Inventory-Revised (OCI-R²⁴).

Study psychiatrists assessed side effects at each visit using a modified version of the Systemic Assessment for Treatment Emergent Events that included 26 items (each rated absent, mild, moderate, or severe)²⁵. Vital signs and weight were measured at each visit; height was measured at baseline and used to calculate Body Mass Index (BMI=mass [kg]/

[height (m)]²). Psychiatrists assessed tics using the Yale Global Tic Severity Scale²⁶ at baseline, and extrapyramidal symptoms using the Simpson-Angus Scale²⁷ and Barnes Akathisia Scale²⁸ at each visit, and the Abnormal Involuntary Movement Scale^{29, 30} at Weeks 0 and 8.

Details about the training of study staff and the reliability of assessments are provided elsewhere¹².

Data Analysis

While focusing on the Maintenance Phase, we included all randomized participants in our primary analyses, since those who entered maintenance did not comprise a randomized sample and therefore would render the results uninterpretable. Of the 20 placebo participants, only three were acute phase responders¹², and two entered maintenance. Thus, the analyses focus on the 80 participants originally randomized to EX/RP or risperidone augmentation.

The primary outcome was the Y-BOCS, which was analyzed using linear mixed models (LMMs). LMMs allow the inclusion of all subjects, irrespective of missing data. Importantly, LMMs are particularly suitable for analyzing maintenance trials such as ours because they produce accurate and unbiased results when data are missing due to patients being dropped because of non-response to treatment³¹. Indeed, studies show that LMMs accurately estimate the results for the entire initial randomized sample even when almost 90% of subjects are dropped from the study due to non-response to treatment³¹, and even when sample sizes are very small³².

Two separate LMMs were employed. To estimate the means at each assessment point, our first LMM used indicator variables to code each assessment point. This model freely estimates each mean at each assessment without constraining them to fit any particular growth curve model. To estimate the slopes of Y-BOCS change, our second LMM used a linear piecewise growth curve model³³, allowing the slopes to change from the Acute to the Maintenance Phase (see Figure 2). As preliminary analyses showed treatment site was unrelated to outcome ($P_s > .184$), it was dropped from further analyses.

As secondary analyses, a Fisher's Exact Test examined the proportion in each treatment group who met response criteria at the end of maintenance (Y-BOCS decrease $\geq 25\%$) or excellent response criteria (Y-BOCS ≤ 12), thereby using the criteria employed in prior studies to enable direct comparison^{2, 5} for these analyses, the last available observation was used. The LMMs were used to examine outcomes from our secondary measures (SAS-SR, QLESQ, HAM-D, BABS, and OCI-R). The significance level for all tests was $\alpha=.05$.

Results

Sample

As shown in Figure 1, of the 100 patients randomized, 44 patients were judged responders (Y-BOCS decrease $\geq 25\%$) at the end of the Acute Phase. Forty entered the Maintenance

Phase (30 EX/RP, 8 risperidone, 2 placebo), and 31 completed it (26 EX/RP, 3 risperidone, 2 placebo). The reasons for dropout are detailed in Figure 1.

Demographic and clinical characteristics of the 30 EX/RP and 8 risperidone patients who entered maintenance are presented in Table 1; the proportion who completed maintenance was significantly higher in EX/RP than in risperidone ($P=.01$). Of the risperidone patients, four continued on the same dose they were receiving at the end of the Acute Phase; four decreased their dose during maintenance to reduce side effects. The final mean risperidone dose of these 8 patients was 1.47 (SD=0.91, range=0.5 to 3.0 mg/day). Twenty of the 30 EX/RP patients who entered maintenance received additional 90-minute sessions (mean=10.30, SD=4.64, range 1–15); seven received the maximum 15 sessions.

Primary Outcome: Y-BOCS

a. Y-BOCS over time—At the end of maintenance treatment, patients originally randomized to acute EX/RP augmentation had significantly lower mean Y-BOCS scores than those originally randomized to risperidone (see Table 2; $b=7.75$, $t(40)=2.76$, $P=.009$, $d=.87$). However, during maintenance, the groups did not significantly differ from one another with respect to change in Y-BOCS (see Figure 2; $b=.12$, $t(33)=1.11$, $P=.276$ for the Treatment $\times$ Time interaction during maintenance). During maintenance, both groups showed a small, statistically significant Y-BOCS improvement ($b=-.09$, $t(26)=-2.47$, $P=.020$, $d=.24$) of 2.2 points.

Exploratory analyses indicated that Y-BOCS change during maintenance was significantly related to Y-BOCS at entry to maintenance, with lower Y-BOCS associated with faster Y-BOCS decreases in both conditions ($r(38)=.57$, $P<.001$). A post-hoc cluster analysis of Y-BOCS slopes during maintenance, Y-BOCS severity at entry to maintenance, and amount of therapy received during maintenance suggested a complex relationship between amount of maintenance EX/RP treatment in minutes (summing 45 and 90-minute sessions) and maintenance outcome: those who improved the most during maintenance (average Y-BOCS slope of -0.20) had minimal OCD symptoms at entry to maintenance (Y-BOCS=8.60 [SD=5.97]) and received on average 680 minutes [SD=155] of maintenance treatment; those who improved less (average Y-BOCS slope of -0.05) had minimal OCD symptoms at entry (Y-BOCS=8.67 [SD=3.56]) but received less maintenance treatment than the former patients (255 minutes [SD=203]; and those whose OCD symptoms did not change during maintenance (average Y-BOCS slope of 0) had the most OCD symptoms at entry to maintenance (Y-BOCS=15.14 [SD=3.18]) and received the most maintenance treatment (1578 minutes [SD=202]).

b. Response Rates—By the end of maintenance treatment, significantly more patients originally randomized to EX/RP than to risperidone achieved response status (Y-BOCS decrease 25%: 28 of 40 [70.0%] in EX/RP; 8 of 40 [20.0%] in risperidone; Fisher's Exact Test $P<.001$), and significantly more patients randomized to EX/RP achieved minimal symptoms (Y-BOCS 12: 20 of 40 [50.0%] in EX/RP; 2 of 40 [5.0%] in risperidone; Fisher's Exact Test $P<.001$). However, of the 30 EX/RP and 8 risperidone responders who entered maintenance, the proportion who maintained their response status did not

significantly differ by treatment (28 of 30 [93.3%] in EX/RP; 8 of 8 [100%] in risperidone; Fisher's Exact Test $P=.619$).

Secondary Outcomes: Change in Secondary Measures Over Time

At the end of maintenance treatment, patients originally randomized to EX/RP had significantly more improvement than patients randomized to risperidone on all secondary outcomes, including measures of depression, functioning, and quality of life ($P_s < .047$, $d_s = .64 - 1.16$), except the BABS, a measure of insight ($P = .128$; see Table 2). Notably, during maintenance, there were no group differences in the rates of change over time on any of the secondary outcomes (all $P_s > .207$ for the Treatment $\times$ Time interactions). The slopes of improvement during maintenance for both treatment conditions were significant (small to medium in size) for all secondary outcomes ($P_s < .01$, $d_s = .19 - .52$), with the exception of the QLESQ ($P = .183$).

Discussion

This paper describes six-month outcomes after augmenting SRIs with EX/RP or risperidone in adults with OCD. EX/RP augmentation was superior to risperidone augmentation in reducing OCD and depression severity and improving quality of life and functioning not only after acute treatment¹² but also six months later. By the end of maintenance, 50% of patients initially randomized to EX/RP augmentation achieved minimal OCD symptoms compared to 5% of those randomized to risperidone augmentation. These data support using EX/RP over antipsychotics for augmenting SRIs in OCD.

To our knowledge, this is the only study to systematically investigate the long term outcome of augmenting SRIs with antipsychotics in OCD. Contrary to our expectations, few patients responded acutely to risperidone (9 of 40), and eight agreed to enter maintenance. Although these eight maintained their OCD gains as long as they were assessed, five did not complete maintenance due to intolerable side effects or increased depression. Thus, risperidone, albeit acutely efficacious for some, was not very effective over time in our sample. The three who completed maintenance were receiving risperidone doses (0.5, 0.75, and 1.0 mg/day) below the mean maximum dose during the Acute (2.2 mg/day) or Maintenance Phases (1.5 mg/day). Low risperidone doses may increase long-term tolerability.

It is important to note that those who responded to augmenting SRIs with EX/RP were likely to maintain their gains (or slightly improve) for an additional six months with maintenance treatment. Thus, even though EX/RP treatment yielded very substantial acute improvement, there was no evidence of a tendency to regress or rebound during maintenance. This result is consistent with our data from a prior randomized trial⁵ in which patients responding to augmenting SRIs with EX/RP were followed for an additional six months⁸. However, despite similar rates of acute response to EX/RP augmentation (80% in the current trial¹² and 74% in the earlier trial⁵), more patients in the current trial met response criteria after six months maintenance (70% versus 41%) and achieved minimal symptoms (50% versus 24%). Differences in study designs may explain the disparity: patients in the current study received more frequent 45-minute maintenance sessions (twice monthly versus once monthly) and could also receive up to 15 additional 90-minute EX/RP sessions during

maintenance if they did not achieve minimal OCD symptoms after the Acute Phase. This suggests that additional treatment may have helped some patients maintain their acute gains. Although the maintenance treatment in the current study is much more intensive (and hence more costly) than the maintenance treatment in the previous study, the superior six month outcomes observed in the current study may warrant the additional investment.

On average, patients randomized to EX/RP and risperidone augmentation exhibited continued improvement during maintenance on most outcomes, but these gains were clinically small. Thus outcome at the end of the Maintenance Phase primarily reflected successful maintenance of acute response, regardless of the treatment received. Indeed, lower OCD severity at entry to maintenance was associated with better outcome in both conditions.

The lack of treatment group differences in the rate of improvement during maintenance in the present study was initially surprising given that 20 of 30 EX/RP patients received additional 90-minute treatment sessions during maintenance. However, those who received additional 90-minute sessions were not a random sample: patients received these 90-minute sessions until they either achieved minimal symptoms or had 15 sessions. In fact, a post-hoc analysis suggested a complex relationship between maintenance outcome and amount of maintenance EX/RP treatment (summing 45 and 90-minute sessions): those whose OCD improved the most during maintenance had minimal OCD symptoms at entry to maintenance and received some maintenance treatment; those who improved less had minimal OCD symptoms at entry but received less maintenance treatment than the former; and those whose OCD symptoms did not change during maintenance did not achieve minimal symptoms by the end of the Acute Phase, continued to receive 90-minute EX/RP sessions, and thus received the most maintenance treatment. These findings suggest that achieving minimal OCD severity with acute treatment and receiving some maintenance therapy were both important ingredients for maximizing EX/RP long-term outcome. However, our study was not designed to investigate this issue prospectively. Future studies should also develop cost-effective methods for delivering EX/RP and should examine what factors determine who will benefit most from maintenance therapy.

This study has several limitations. The first is sample size. For ethical considerations, non-responders to acute treatment were referred for other treatments. Thus, only 8 risperidone patients entered the Maintenance Phase, which calls for caution in generalizing the long term outcome of risperidone from these data. Nevertheless, studies show that LMM growth models in which almost 90% of cases are dropped for non-response still produce unbiased and accurate estimates of the actual population parameters for the entire initial randomized sample³¹. A second limitation is that the Maintenance Phase lasted only six months. However, it is difficult to control all treatment that patients receive over an extended period of time, which is why studies with longer follow-up periods^{34, 35} adopt naturalistic designs. Finally, patients receiving EX/RP were not blind to their treatment and had more clinician contact than those receiving risperidone. Yet, our prior study⁵ that compared EX/RP augmentation to a psychotherapy control suggests that blindness to therapy and clinician contact alone cannot explain the superiority of EX/RP.

In summary, OCD patients on SRIs who responded acutely to EX/RP or risperidone augmentation were likely to maintain their gains over six months with some continued treatment. However, many more EX/RP than risperidone patients responded acutely and thus entered the Maintenance Phase. As a result, augmenting SRIs with EX/RP yielded superior outcomes than risperidone six months later. It is important to note that during the 8-week Acute Phase of treatment, of the 50 patients who received EX/RP augmentation, 30 were responders, whereas of the 50 who received risperidone, only 8 were responders. Taken together, the results of the Acute and the Maintenance treatment phases strongly support augmenting SRIs with EX/RP rather than with risperidone in adults with OCD. The data also suggest that ongoing EX/RP treatment can help many patients maintain their acute gains. Developing effective and cost-effective ways to deliver EX/RP to OCD patients will advance public health.

Acknowledgements

The authors thank the patients who participated as well as the staff of the Center for the Study and Treatment of Anxiety and the Anxiety Disorders Clinic who helped in the conduct of this study, including the expert former research assistance by Samantha Farris, M.A., Jessica McCarthy, M.A., Rena Staub, LMSW, Liane Hunter, B.A., and Josephine Curry, B.A. We also thank Dr. Eva Petkova, Ph.D., who is currently affiliated with the NYU Medical Center, for her involvement in the initial study design and data plan. Also many thanks to Rebecca Yeh, B.A. for her help in editing the manuscript. These contributors report no financial or other relationship relevant to the subject of this article.

Dr. Foa has received research support from Transcept Pharmaceuticals, Neuropharm Ltd, Pfizer, Solvay, Eli Lilly, SmithKline Beecham, GlaxoSmithKline, Cephalon, Bristol-Myers Squibb, Forest, Ciba-Geigy, Kali-Duphar, and APA. She has been a speaker for Pfizer, GlaxoSmith-Kline, Forest, and APA; and she receives royalties from the sale of two books on obsessive-compulsive disorder from Bantam and Oxford University Press. Dr. Simpson has received research support from Transcept Pharmaceuticals, Neuropharm Ltd., and Janssen Pharmaceuticals, consulting fees from Pfizer Inc, Jazz Pharmaceuticals, and Quintiles, Inc., honoraria from the American Society of Clinical Psychopharmacology, and royalties from Cambridge University Press and UpToDate, Inc. Dr. Liebowitz has received research support from Allergan, Pfizer, GSK, Astra Zeneca, Forest, Tikvah, Avera, Eli Lilly, Novartis, Sepracor, Horizon, Johnson and Johnson, Pherin, PGX Health, Abbott, Jazz, MAP, Takeda, Wyeth, Cephalon, Indevus, Endo, Ortho-McNeil, and Gruenthal. He has served as a consultant for Astra Zeneca, Wyeth, Pfizer, Takeda, Pherin, Lilly, Otsuka, Eisai, Avera, Tikvah, Concert, J and J, Forest, and Sunovion. In addition, Dr. Liebowitz has licensing agreements for rating scale and/or electronic data capture devices with GSK, Pfizer, Avera, Tikvah, Endo, Lilly, Indevus, Servier; he holds the copyright of the Liebowitz Social Anxiety Scale; and he holds equity ownership in Pherin Pharmaceuticals.

Funding/Support: This study was funded by NIMH grants R01 MH-45404 (PI: Dr. EB Foa) and R01 MH-45436 (PI: Dr. HB Simpson).

Role of Sponsor: The NIMH had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

References

1. American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. *Am J Psychiatry*. 2007; 164:1–56. [PubMed: 17202533]
2. Simpson HB, Huppert JD, Petkova E, Foa EB, Liebowitz MR. Response versus remission in obsessive-compulsive disorder. *J Clin Psychiatry*. 2006; 67(2):269–276. [PubMed: 16566623]
3. Tolin DF, Maltby N, Diefenbach GJ, Hannan SE, Worhunsky P. Cognitive-behavioral therapy for medication nonresponders with obsessive-compulsive disorder: a wait-list-controlled open trial. *J Clin Psychiatry*. 2004; 65(7):922–931. [PubMed: 15291681]
4. Kampman M, Keijsers G, Hoogduin C, Verbraak M. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine. *Acta Psychiatr Scand*. 2002; 106(4):314–319. [PubMed: 12225499]

5. Simpson HB, Foa EB, Liebowitz MR, Ledley DR, Huppert JD, Cahill S, Vermes D, Schmidt AB, Hembree E, Franklin M, Campeas R, Hahn CG, Petkova E. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder. *Am J Psychiatry*. 2008; 165(5):621–630. [PubMed: 18316422]
6. Tenneij NH, van Megan HJ, Denys DA, Westenberg HG. Behavior therapy augments response of patients with obsessive-compulsive disorder responding to drug treatment. *J Clin Psychiatry*. 2005; 66(9):1169–1175. [PubMed: 16187776]
7. Tundo A, Salvati L, Busto G, Di Spigno D, Falcini R. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study. *J Clin Psychiatry*. 2007; 68(10):1552–1556. [PubMed: 17960971]
8. Foa EB, Simpson HB, Liebowitz MR, Powers MB, Rosenfield D, Cahill SP, Campeas R, Franklin M, Hahn CG, Hembree EA, Huppert JD, Schmidt AB, Vermes D, Williams MT. Six-month follow-up of a randomized controlled trial augmenting serotonin reuptake inhibitor treatment with exposure and ritual prevention for obsessive-compulsive disorder. *J Clin Psychiatry*. 2013; 74(5):464–469. [PubMed: 23759449]
9. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. *Mol Psychiatry*. 2006; 11(7):622–632. [PubMed: 16585942]
10. Dold M, Aigner M, Lanzenberger R, Kasper S. Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized, placebo-controlled trials. *Int J Neuropsychopharmacol*. 2012:1–18.
11. Matsunaga H, Nagata T, Hayashida K, Ohya K, Kiriike N, Stein DJ. A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder. *J Clin Psychiatry*. 2009; 70(6):863–868. [PubMed: 19422759]
12. Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J Jr, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R. Cognitive-Behavioral Therapy vs Risperidone for Augmenting Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder: A Randomized Clinical Trial. *JAMA Psychiatry*. 2013
13. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. II. Validity. *Arch Gen Psychiatry*. 1989; 46(11):1012–1016. [PubMed: 2510699]
14. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability. *Arch Gen Psychiatry*. 1989; 46(11):1006–1011. [PubMed: 2684084]
15. Hamilton M. A Rating Scale for Depression. *Journal of Neurology, Neurosurgery & Psychiatry*. 1960; 23:56–62.
16. First, MB.; Spitzer, RL.; Gibbon, M.; Williams, JB. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition. New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1996.
17. Kozak, MJ.; Foa, EP. Mastery of Obsessive-Compulsive Disorder. Graywind Publications Incorporated; 1997.
18. McDougle CJ, Epperson CN, Pelton GH, Wasyluk S, Price LH. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. *Arch Gen Psychiatry*. 2000; 57(8):794–801. [PubMed: 10920469]
19. Erzegovesi S, Guglielmo E, Siliprandi F, Bellodi L. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study. *Eur Neuropsychopharmacol*. 2005; 15(1):69–74. [PubMed: 15572275]
20. Hollander E, Baldini Rossi N, Sood E, Pallanti S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. *Int J Neuropsychopharmacol*. 2003; 6(4):397–401. [PubMed: 14604454]
21. Eisen JL, Phillips KA, Baer L, Beer DA, Atala KD, Rasmussen SA. The Brown Assessment of Beliefs Scale: reliability and validity. *Am J Psychiatry*. 1998; 155(1):102–108. [PubMed: 9433346]

22. Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. *Psychopharmacol Bull.* 1993; 29(2):321–326. [PubMed: 8290681]
23. Weissman MM, Bothwell S. Assessment of social adjustment by patient self-report. *Arch Gen Psychiatry.* 1976; 33(9):1111–1115. [PubMed: 962494]
24. Foa EB, Huppert JD, Leiberg S, Langner R, Kichic R, Hajcak G, Salkovskis PM. The Obsessive-Compulsive Inventory: Development and validation of a short version. *Psychological Assessment.* 2002; 14(4):485–495. [PubMed: 12501574]
25. Levine J, Schooler NR. SAFTEE: a technique for the systematic assessment of side effects in clinical trials. *Psychopharmacol Bull.* 1986; 22(2):343–381. [PubMed: 3774930]
26. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, Cohen DJ. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. *J Am Acad Child Adolesc Psychiatry.* 1989; 28(4):566–573. [PubMed: 2768151]
27. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. *Acta Psychiatr Scand Suppl.* 1970; 212:11–19. [PubMed: 4917967]
28. Barnes TR. The Barnes Akathisia Rating Scale--revisited. *J Psychopharmacol.* 2003; 17(4):365–370. [PubMed: 14870947]
29. Guy, W. ECDEU Assessment Manual for Psychopharmacology. Rockville, Maryland: U.S. Department of Health, Education, and Welfare; 1976.
30. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. *Hosp Community Psychiatry.* 1988; 39(11):1172–1177. [PubMed: 2906320]
31. Hedeker, D.; Gibbons, RD. Longitudinal Data Analysis. Hoboken: John Wiley & Sons, Inc.; 2006.
32. Maas, Cora JM.; Hox, Joop J. Sufficient sample sizes for multilevel modeling. *Methodology: European Journal of Research Methods for the Behavioral and Social Sciences.* 2005:86–92. 1.3.
33. Singer, JD.; Willett, JB. Applied Longitudinal Data Analysis. New York: Oxford University Press; 2003.
34. Van Oppen P, Hoekstra RJ, Emmelkamp PM. The structure of obsessive-compulsive symptoms. *Behav Res Ther.* 1995; 33(1):15–23. [PubMed: 7872933]
35. Whittal ML, Robichaud M, Thordarson DS, McLean PD. Group and individual treatment of obsessive-compulsive disorder using cognitive therapy and exposure plus response prevention: a 2-year follow-up of two randomized trials. *J Consult Clin Psychol.* 2008; 76(6):1003–1014. [PubMed: 19045968]

Clinical Points

1. While serotonin reuptake inhibitors are the only medications approved by the FDA to treat OCD, many patients remain quite symptomatic.
2. For partial SRI responders, practice guidelines recommend adding either Exposure and Response Prevention (EX/RP) or antipsychotics (e.g., risperidone).
3. The results strongly support augmenting SRIs with EX/RP rather than with risperidone in adults with OCD.
4. The results also suggest that extending EX/RP beyond the 17 acute treatment sessions (up to 30 sessions) helps many patients maintain their gains.

Figure 1. Flow Chart of Patients in Study

* Reasons for not completing maintenance:

EX/RP: increasing depression (n=1); wanted to change SRI medication (n=1), unable to travel to site (n=1), lost to follow-up (n=1);

Risperidone: side effects too great (n=2); increasing depression (n=2); lost to follow-up (n=1)

Figure 2. Change in Severity of Obsessive-Compulsive Disorder

Plot of the piecewise growth curve for the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) for patients receiving EX/RP ($n=40$) or risperdone ($n=40$). At the end of the Maintenance Phase, those randomized to EX/RP had significantly lower mean Y-BOCS scores (Week 32: $b=7.75$, $P=.009$). Slopes during the Maintenance Phase did not differ (Weeks 8–32: $b=.12$, $P=.276$).

Table 1

Characteristics of Entrants to the Maintenance Phase

	EX/RP (n=30)	RIS (n=8)
Age, mean (SD), y	34.47 (13.09)	42.25 (11.73)
Female, No. (%)	17 (57)	4 (50)
White, No. (%)	28 (93)	8 (100)
Marital Status, No. (%):		
Single	17 (57)	3 (38)
Married-Partnered	11 (37)	3 (38)
Divorced-Separated	2 (7)	2 (25)
Week 0 Y-BOCS, mean (SD)	27.50 (3.88)	24.13 (4.29)
Week 8 Y-BOCS, mean (SD)	11.67 (5.36)	11.13 (6.71)
Week 0 HDRS, mean (SD)	6.87 (5.18)	10.00 (6.09)
Week 8 HDRS, mean (SD)	4.30 (3.71)	5.13 (3.23)

Abbreviations: EX/RP, Exposure and Ritual Prevention; HDRS, Hamilton Depression Rating Scale; SD, standard deviation; SMT, Stress Management Training; y, year; Y-BOCS, Yale-Brown Obsessive Compulsive Scale.

Table 2

Outcomes over Time from Augmenting Serotonin Reuptake Inhibitors

Outcomes ^d	EX/RP			Risperidone		
	Week 0	Week 8	Week 32	Week 0	Week 8	Week 32
Primary outcome, mean (SE)						
Y-BOCS	27.18 (0.65)	13.17 (1.20)	10.95 (1.24)	26.13 (0.65)	22.99 (1.27)	18.70 (2.52)
Secondary outcome, mean (SE)						
SAS-SR	2.25 (0.07)	1.88 (0.07)	1.74 (0.07)	2.25 (0.07)	2.15 (0.07)	2.15 (0.14)
QLESQ	57.83 (2.38)	70.64 (2.25)	70.43 (2.64)	52.28 (2.38)	54.53 (2.37)	48.33 (5.36)
HDRS	7.80 (0.91)	4.64 (0.78)	3.53 (0.66)	9.82 (0.92)	8.13 (0.83)	6.70 (1.40)
BABS	6.13 (0.68)	2.53 (0.57)	1.62 (0.47)	5.73 (0.68)	4.61 (0.61)	3.21 (0.91)
OCI-R	29.20 (1.92)	11.49 (0.95)	6.87 (0.91)	26.45 (1.92)	23.41 (1.64)	13.25 (2.09)

Abbreviations: BABS, Brown Assessment of Beliefs; EX/RP, Exposure and Ritual Prevention; HDRS, Hamilton Depression Rating Scale; OCI-R, Obsessive Compulsive Inventory-Revised; QLESQ, Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form; SAS-SR, Social Adjustment Scale-Self Report; SE, Standard Error; Y-BOCS, Yale-Brown Obsessive Compulsive Scale.

^d Estimated means (standard errors) from linear mixed models (see text) using all randomized to EX/RP (n=40) and all randomized to risperidone (n=40). Patients randomized to EX/RP had significantly better Week 32 scores than patients randomized to risperidone on the Y-BOCS and all secondary outcomes except the BABS.